Gilead Sciences lures Arcus CMO to oversee its oncology portfolio

20 July 2021

US oncology-focussed biotech Arcus Biosciences (NYSE: RCUS) today announced that Dr Bill Grossman will transition out of his role as chief medical officer at Arcus and into a role at Gilead Sciences (Nasdaq: GILD) as senior vice president of oncology clinical research to oversee Gilead’s clinical-stage oncology portfolio.

This will include leading Gilead’s efforts in the company’s alliance with Arcus to co-develop and co-commercialize Arcus’s portfolio of investigational cancer medicines. Dr Kartik Krishnan, senior vice president, clinical development at Arcus, will assume full leadership of the Arcus clinical development program and continue to work closely with Dr Grossman at Gilead. The transition will be effective July 26, 2021.

In his new role, Dr Grossman will be Arcus’ point of contact at Gilead for development activities across the Arcus programs, and this move reinforces both companies’ commitment to working together to advance important new medicines for people with cancer.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK